---
title: "ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | PROK Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286589812.md"
description: "ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | PROK Stock News"
datetime: "2026-05-15T07:45:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286589812.md)
  - [en](https://longbridge.com/en/news/286589812.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286589812.md)
generator: "portal-rs"
---

# ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | PROK Stock News

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights | PROK Stock News

### Related Stocks

- [PROK.US](https://longbridge.com/en/quote/PROK.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [ProKidney Q2 FY26 net loss widens to $46.44 million; revenue falls to $150,000](https://longbridge.com/en/news/295444283.md)
- [ProKidney (NASDAQ:PROK) Stock Price Up 7.6%  - Should You Buy?](https://longbridge.com/en/news/298066031.md)
- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**